Januvia

Merck Says Januvia Effective In Type 2 Diabetes

Merck & Co Inc has said that Januvia, its oral, once-daily medicine for type 2 diabetes has shown promise in combating the disease and had significantly reduced //blood sugar levels. This was true when the drug was used alone or in conjunction with two commonly used therapies (metformin or pioglita...

For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors

... that the shortcomings of Merck's DPP-IV inhibitor januvia include less glucose-lowering compared to metformi...d clinicians indicate that although the feature of januvia that they would most like to see improved in futur...s its glucose-lowering efficacy, a lower cost than januvia would be a more persuasive factor in their decisio...

Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes

...ontrol, but LDL-C increased in patients on both of these treatment regimens. In total, 169 patients were randomized to receive either Welchol (n=57), januvia (n=56) or Avandia (n=56).(1) "Seventy percent of patients with type 2 diabetes have elevated LDL cholesterol and are not at the recommended goal ...

Popular diabetes treatment could trigger pancreatitis, pancreatic cancer

... risk factors for pancreatitis and, with time, pancreatic cancer in humans. januvia is marketed by Merck & Co. Inc. Sitagliptin is a member of a new class of d...ion between Byetta, a drug used to treat Type 2 diabetes that is related to januvia in its intended actions, and pancreatitis has already been reported, prompt...

Amylin Pharmaceuticals Reports First Quarter Financial Results

...mpared to three of the newest widely-accepted diabetes therapies, including januvia and Actos. We are on track to submit our NDA filing by the end of this quar...ed superior glucose control, with weight loss, compared to maximum doses of januvia or Actos(R) (pioglitazone). Announced decision to initiate a large ...

Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes

...negotiations are important when improving the formulary position of Merck's januvia and Amylin/Eli Lilly's Byetta than say safety or efficacy gains leading to downstream cost savings. Both recent entrants in the antidiabetic market, januvia and Byetta are covered on 85 percent of health plans. "Our survey rev...

New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes

...here were no reports of hypoglycemia in either the januvia or the placebo groups. Advanced age contributes to...BOR, Md. (Business Wire EON) November 21, 2008 -- januvia is indicated, as an adjunct to diet and exercise, ...ic control in adult patients with type 2 diabetes. januvia should not be used in patients with type 1 diabete...

AstraZeneca's Purplepill.com Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008

... 3 % Veramyst (veramyst.com) N/A 538 N/A januvia (januvia.com) 118 507 329 % Lyrica (lyrica...in the category in Q2 2008 versus year ago. -- Merck's diabetes treatment januvia increased marketing activity beginning in the second half of last year, res...

Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes

...oglobin A1c, in moderately controlled diabetic patients. -- GlycoMark(R) is best marker for efficacy for blockbuster drugs Byetta (Amylin/Lilly) and januvia (Merck) in moderately controlled patients. -- Inclusion in the International Diabetes Federation (IDF) Global Diabetes Care Guidelines. -- Establi...

A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market

...st liraglutide to become the clinical gold standard among the agents covered in our analysis." About the Report Type 2 Diabetes: Blockbuster-Bound januvia Addresses Physicians' Concern over Hypoglycemia is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts wit...

Januvia in Medical Technology

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improve...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from an investigational study released at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that initial combination therapy with Januvia(TM) (sitagliptin) and metformin demonstrated significant improvement in markers of...

Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

...t they are reluctant to prescribe ACTOS or any other product containing ACTOS (i.e., ACTOplus met). The GfK Market Measures research also identified januvia and Januvamet as the therapies most likely to benefit from the Avandia switches implemented by all groups of physicians treating type 2 patients. "W...

Januvia in Biological Technology

Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011

...ne agent in type 2 diabetes treatment and its success will propel Merck into the diabetes market, giving the company 15 percent of the market in 2011. januvia will become the second-leading blockbuster in the market, behind only Takeda's Actos. Surveyed primary care physicians ranked Merck as best for produc...